PXS-4728 is under clinical development by Pharmaxis and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PXS-4728’s likelihood of approval (LoA) and phase transition for Inflammation took place on 02 Dec 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PXS-4728 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PXS-4728 overview

BI-1467335 (PXS-4728) is under development for the treatment of inflammation and Parkinson's disease. The drug candidate is administered orally as a film coated tablet and intravenous route. It acts by targeting semicarbazide-sensitive amino-oxidase (SSAO)/vascular adhesion protein-1. It was also under development for the treatment of chronic obstructive pulmonary disease, non-proliferative diabetic retinopathy (NPDR), non-alcoholic steatohepatitis (NASH), and cystic fibrosis.

Pharmaxis overview

Pharmaxis is a pharmaceutical research company that develops and commercialize healthcare products. The company provides products such as aridol which identify twitchy and assist in diagnosing and managing asthma, and bronchitol which restores normal lung hydration, improves lung function and relieves the mucus burden in the lungs of patients. It offers products pipeline such as orbital dry powder inhaler, PXS-4728A, LOXL-2 and ASM8. Pharmaxis provides solutions for cystic fibrosis, bronchiectasis, asthma and chronic obstructive pulmonary disease and inflammatory and fibrotic diseases such as nonalcoholic steatohepatitis and pulmonary fibrosis, among others. The company operates in Australia. Pharmaxis is headquartered in Sydney, New South Wales, Australia.

Quick View PXS-4728 LOA Data

Report Segments
  • Innovator
Drug Name
  • PXS-4728
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Immunology
  • Metabolic Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.